» Articles » PMID: 28212944

Acute and Long-term Effects of Adolescent Methylphenidate on Decision-making and Dopamine Receptor MRNA Expression in the Orbitofrontal Cortex

Overview
Journal Behav Brain Res
Date 2017 Feb 19
PMID 28212944
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Though commonly used as a treatment for ADHD, the psychostimulant methylphenidate (MPH) is also misused and abused in adolescence in both clinical and general populations. Although MPH acts via pathways activated by other drugs of abuse, the short- and long-term effects of MPH on reward processing in learning and decision-making are not clearly understood. We examined the effect of adolescent MPH treatment on a battery of reward-directed behaviors both in adolescence during its administration and in adulthood after its discontinuation. We further measured whether MPH had lasting effects on dopamine receptor mRNA expression in orbitofrontal cortex (OFC) that may correspond with behavior. Long-Evans rats were injected with MPH (0, 1, 2.5, or 5mg/kg IP) twice daily from middle to late adolescence (PD38-57). During adolescence, the high dose of MPH reduced preference for large rewards in a Reward Magnitude Discrimination task, but did not affect preference for smaller-sooner rewards in a Delay Discounting task. In adulthood, after discontinuation of MPH, animals previously treated with the moderate dose of MPH showed improved acquisition, but not reversal, in a Reversal Learning task. MPH exposure did not increase preference for large-risky rewards in a Risk task in adulthood. We then quantified mRNA expression of D1, D2, and D3 receptors in the OFC using qPCR. MPH increased mRNA expression of dopamine D3 receptor subtype, but not D1 or D2. Overall, these results indicate that MPH has both immediate and lasting effects on reward-dependent learning and decisions, as well as dopaminergic function in rodents.

Citing Articles

Methylphenidate, but not citalopram, decreases impulsive choice in rats performing a temporal discounting task.

Koloski M, Terry A, Lee N, Ramanathan D Front Psychiatry. 2024; 15:1385502.

PMID: 38779546 PMC: 11109432. DOI: 10.3389/fpsyt.2024.1385502.


Exploration of Epigenetic State Hyperdopaminergia (Surfeit) and Genetic Trait Hypodopaminergia (Deficit) During Adolescent Brain Development.

Blum K, Bowirrat A, Gondre Lewis M, Simpatico T, Ceccanti M, Steinberg B Curr Psychopharmacol. 2021; 10.

PMID: 34707969 PMC: 8547282. DOI: 10.2174/2211556010666210215155509.


Challenges and Opportunities in Animal Models of Gambling-like Behavior.

Vonder Haar C Curr Opin Behav Sci. 2020; 31:42-47.

PMID: 32864398 PMC: 7451966. DOI: 10.1016/j.cobeha.2019.10.013.


Effects of methylphenidate on the aggressive behavior, serotonin and dopamine levels, and dopamine-related gene transcription in brain of male Nile tilapia (Oreochromis niloticus).

Batalhao I, Lima D, Russi A, Boscolo C, Silva D, Pereira T Fish Physiol Biochem. 2019; 45(4):1377-1391.

PMID: 31054043 DOI: 10.1007/s10695-019-00645-2.


PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.

Stevens T, Sangkuhl K, Brown J, Altman R, Klein T Pharmacogenet Genomics. 2019; 29(6):136-154.

PMID: 30950912 PMC: 6581573. DOI: 10.1097/FPC.0000000000000376.

References
1.
Wargin W, Patrick K, Kilts C, Gualtieri C, Ellington K, Mueller R . Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther. 1983; 226(2):382-6. View

2.
Marco E, Adriani W, Ruocco L, Canese R, Sadile A, Laviola G . Neurobehavioral adaptations to methylphenidate: the issue of early adolescent exposure. Neurosci Biobehav Rev. 2011; 35(8):1722-39. DOI: 10.1016/j.neubiorev.2011.02.011. View

3.
Caballero A, Tseng K . GABAergic Function as a Limiting Factor for Prefrontal Maturation during Adolescence. Trends Neurosci. 2016; 39(7):441-448. PMC: 4930717. DOI: 10.1016/j.tins.2016.04.010. View

4.
Vanhauwe J, Josson K, Luyten W, Driessen A, Leysen J . G-protein sensitivity of ligand binding to human dopamine D(2) and D(3) receptors expressed in Escherichia coli: clues for a constrained D(3) receptor structure. J Pharmacol Exp Ther. 2000; 295(1):274-83. View

5.
Berridge C, Devilbiss D . Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. Biol Psychiatry. 2010; 69(12):e101-11. PMC: 3012746. DOI: 10.1016/j.biopsych.2010.06.023. View